After responding to platinum-based chemotherapy
*LYNPARZA + bevacizumab was studied against bevacizumab + placebo.
The PAOLA-1 study evaluated advanced ovarian cancer patients who received LYNPARZA + bevacizumab after responding to platinum-based chemotherapy and bevacizumab. The results presented are a subset of the LYNPARZA PAOLA-1 study and should be discussed with your doctor. In the subset of 387 women with HRD-positive advanced ovarian cancer, 255 women received LYNPARZA + bevacizumab and 132 women received bevacizumab + placebo.
WOMEN RECEIVING LYNPARZA + BEVACIZUMAB DID NOT SEE THEIR HRD-POSITIVE ADVANCED OVARIAN CANCER GROW OR RETURN FOR A MEDIAN OF OVER 3 YEARS (37.2 MONTHS) COMPARED TO 17.7 MONTHS FOR WOMEN ON BEVACIZUMAB + PLACEBO.*
LYNPARZA + bevacizumab lowered the risk of disease progression or death by 67% compared to bevacizumab. 168 out of 255 women on LYNPARZA + bevacizumab did not see their cancer grow or return compared to 40 out of 132 women on bevacizumab + placebo.*
*Because of the design of this study, the statistical meaning of these results may be limited. Talk to your doctor to see if LYNPARZA + bevacizumab is right for you
HRD* is an important biomarker of advanced ovarian cancer. An HRD test assesses the DNA profile of your tumor, including different mutations and other changes to your DNA. Approximately half of these are BRCA mutations, so even if you are BRCA-negative you could still be HRD-positive.
HRD might be more common than you think
~50% of women with advanced ovarian cancer test positive for HRD.
Knowing your HRD status as early as possible may determine whether LYNPARZA + bevacizumab is a treatment option for you.
*Homologous recombination deficiency.
LYNPARZA + bevacizumab: two proven medicines, one combination
Your doctor may prescribe your initial platinum-based chemotherapy treatment on its own or in combination with bevacizumab. Once you have responded to chemotherapy, your doctor may prescribe LYNPARZA + bevacizumab as maintenance therapy.
Working with your doctor can give you the reassurance that you are considering all of your options. Together you can go through the possibilities and decide on a unique treatment plan for you.
You’ll most likely discuss the following steps, including maintenance therapy, which may help prevent your advanced ovarian cancer from growing or returning.
CONSIDERATIONS FOR FIRST-LINE TREATMENT PLAN
Testing
Tests are used to confirm diagnoses and help create a treatment plan.
Your doctor can test for BRCA and HRD*, which are important biomarkers in advanced ovarian cancer and can help inform what therapies may work for you.
Surgery
Your doctor will discuss your surgical options and whether surgery is right for you.
Chemotherapy
Chemotherapy may be prescribed before or after surgery. It can be used on its own or in combination with other therapies.
Maintenance therapy
Maintenance therapy may help preserve the progress you achieved on chemotherapy.
Your doctor may recommend maintenance therapy using certain treatments in combination or on their own.
*Homologous recombination deficiency.
If your doctor has prescribed LYNPARZA, you may have questions. The AstraZeneca Access 360TM program can help. We can answer your questions about insurance coverage, out-of-pocket costs, and patient assistance programs. To learn more about the Access 360 program, please call 1-844-ASK-A360 (1-844-275-2360)1-844-ASK-A360 (1-844-275-2360) Monday - Friday, 8 AM - 8 PM EST, or visit www.MyAccess360.com.
This is based on commercially insured patients. The average monthly cost for LYNPARZA may be greater than $0 for some patients.
If you have any questions about LYNPARZA, speak with one of our specially trained nurses.
To speak with a nurse, call 1-800-770-8337call 1-800-770-8337.
Take LYNPARZA exactly as your doctor tells you. Two tablets (300 mg per dose), twice a day, totaling four tablets each day by mouth (600 mg daily dose). Bevacizumab is targeted therapy, not chemotherapy.
Take doses 12 hours apart with or without food.
Images do not represent the actual size of the tablets.
Your doctor will determine how long you receive LYNPARZA + bevacizumab as maintenance therapy.
Each treatment plan is unique and any questions you might have should be discussed with your doctor.
Foods to avoid Avoid grapefruit, grapefruit juice, Seville oranges and Seville orange juice during treatment with LYNPARZA since they may increase the level of LYNPARZA in your blood.
If you miss a doseTake your next dose at the usual scheduled time. Do not take an extra dose to make up for the one you missed.
If you take too muchCall your doctor or go to the nearest hospital emergency room right away.
Learn about how to take LYNPARZA + bevacizumab, data from clinical trials, side effects, and dosing information
DOWNLOAD
LYNPARZA Patient Brochure
Learn more about the potential side effects of LYNPARZA and how you should work with your doctor to manage them.
DOWNLOAD
Tips for Managing Your Treatment Brochure
Our Caregiver Brochure provides useful tips and information. Learn more about the importance of looking after yourself as a caregiver.
DOWNLOAD
LYNPARZA Caregiver Brochure
Your submission was successful.
LYNPARZA is a prescription medicine used to treat adults who have:
It is not known if LYNPARZA is safe and effective in children.
LYNPARZA may cause serious side effects, including:
Bone marrow problems called Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML). Some people who have ovarian cancer or breast cancer and who have received previous treatment with chemotherapy, radiotherapy, or certain other medicines for their cancer have developed MDS or AML during treatment with LYNPARZA. MDS or AML may lead to death. If you develop MDS or AML, your healthcare provider will stop treatment with LYNPARZA.
Symptoms of low blood cell counts are common during treatment with LYNPARZA, but can be a sign of serious bone marrow problems, including MDS or AML. Symptoms may include weakness, weight loss, fever, frequent infections, blood in urine or stool, shortness of breath, feeling very tired, bruising or bleeding more easily.
Your healthcare provider will do blood tests to check your blood cell counts:
Lung problems (pneumonitis). Tell your healthcare provider if you have any new or worsening symptoms of lung problems, including shortness of breath, fever, cough, or wheezing. Your healthcare provider may do a chest x-ray if you have any of these symptoms. Your healthcare provider may temporarily or completely stop treatment if you develop pneumonitis. Pneumonitis may lead to death.
Before taking LYNPARZA, tell your healthcare provider about all of your medical conditions, including if you:
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Taking LYNPARZA and certain other medicines may affect how LYNPARZA works and may cause side effects.
How should I take LYNPARZA?
What should I avoid while taking LYNPARZA?
Avoid grapefruit, grapefruit juice, Seville oranges, and Seville orange juice during treatment with LYNPARZA since they may increase the level of LYNPARZA in your blood.
LYNPARZA may cause serious side effects (see above). The most common side effects of LYNPARZA are:
These are not all the possible side effects of LYNPARZA. Call your healthcare provider for medical advice about side effects.
You may report side effects related to AstraZeneca products by clicking here. If you prefer to report these to the FDA, either visit www.FDA.gov/medwatch or call 1-800-FDA-1088.
Please click here for complete Prescribing Information, including Patient Information (Medication Guide).
LYNPARZA may cause serious side effects, including:
Bone marrow problems called Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML). Some people who have ovarian cancer or breast cancer and who have received previous treatment with chemotherapy, radiotherapy, or certain other medicines for their cancer have developed MDS or AML during treatment with LYNPARZA. MDS or AML may lead to death. If you develop MDS or AML, your healthcare provider will stop treatment with LYNPARZA.
